Shanghai General Healthy Information and Technology Co. Ltd. (605186) fair value: what the stock is really worth
We calculate from audited financials what Shanghai General Healthy Information and Technology Co. Ltd. is really worth. The fair value tells you whether the price is too high or too low, the quality score (0 to 100) how solid the business behind it is. 26 models, 37 quality factors, updated daily, free.
Compare price with fair valuebelow fair value = cheap, above = expensive
Check the quality50 and up solid, 75 and up strong
Watch it or check another stockalert when fair value or trend changes
SGShanghai General Healthy Information and Technology Co. Ltd.605186 · SHG
Price¥24.76
Fair Value¥4.98
Upside−79.9%
Quality65/100
A solid business, but trading 397% above our fair value of ¥4.98.
As of Aug 17, 2026, the fair value of Shanghai General Healthy Information and Technology Co. Ltd. is ¥4.98 per share against a price of ¥24.76, so the fair value sits 80% below the price. A model estimate from reported figures, not an analyst target.
!Mixed Growth (revenue 5y +3.8 %/yr)
!Thin margins · 8.9% net margin
✓Low debt · generates free cash flow
!Trails peers (5/14)
!Narrow moat 34/100
!Evidence only low, so the estimate is less certain
!Weak on past: 9 out of 100
!Weak on dividend: 2 out of 100
Evidence: LowRange ¥3.73 to ¥6.22
Fair value as of: Aug 17, 2026
From 25 valuation models · updated 25 days ago
Share price −7.4% over the past month.
This is the short version. In the app for Shanghai General Healthy Information and Technology Co. Ltd.:
Watch Shanghai General Healthy Information and Technology Co. Ltd. for free, get notified when fair value or trend changes. Plus fair value for all 35,000+ stocks, 14 days of Pro free, no card.Watch for free
69 individual criteria per stock, every one traceable See the method →
What matters now
The price sits above even our optimistic bull case (¥6.22). The favourable scenario is already priced in.
The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution.
Solid but not exceptional quality (65/100) and above fair value, neither a clear bargain nor a standout compounder.
Price vs Fair Value (5 years)
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Aug 17, 2026.
How to read this chart
60‑month range ¥17.03 – ¥54.34 · fair‑value band ¥3.73 – ¥6.22 · the ¥24.76 price screens above the ¥4.98 fair value. Dashed = 300-day average. As of Aug 17, 2026.
Shanghai General Healthy Information and Technology Co. Ltd. (605186) currently trades at ¥24.76, while our model-based Fair Value estimate is ¥4.98, implying the stock looks roughly 397.3% overvalued today. The Quality Score stands at 65/100 (solid quality), in the Healthcare sector. Bull case: the Growth DCF group reads highest at a median of ¥7.46 per share, and 0 of the 25 models we run sit above the ¥24.76 price. Bear case: the Earnings-Based group reads lowest at ¥3.83, and 25 of the 25 models stay below the price. Evidence for this calculation is low.
Over the trailing twelve months, Shanghai General Healthy Information and Technology Co. Ltd. generated revenue of 344M CNY at a net margin of 8.9%. Revenue declined 1.4% year over year. It earns a return on equity of 2.2%. Net debt stands at 2.4M CNY. Fundamentals as of Aug 17, 2026
Scenario range: ¥3.73 (bear) to ¥6.22 (bull), the price of ¥24.76 sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target. The share trades about 32% below its 52-week high and 36% above its 52-week low, currently above its 200-day average. For context, the median of 10 Healthcare peers we cover trades at −31% fair-value upside, at −80%, 605186 screens richer than that median.
Fair Value models
Based on fiscal year 2025 figures (about 8 months old). Earnings retained since then (¥0.1601 per share) are deliberately not added.
Each model values the company its own way; the fair value above is the evidence-weighted blend. Evidence (0 to 100) shows how complete a model's inputs are. How we calculate →
Note: the current price implies far more future growth than the conservative anchors of our models allow (base growth is deliberately capped, we do not regard such extreme rates as sustainable). Our models are not designed for expectations this high; that is why the individual models scatter extremely (¥0.3800 to ¥9.50). Read the values as a conservative anchor, not as a price target.
ModelBear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target.Evidence
Free, no payment details. Unsubscribe anytime in one click.
Key figures & financial health
P/E ratio107.7
P/S ratio9.59P/E × margin
EPS (TTM)¥0.2300price ÷ EPS = P/E 107.7
Dividend yield0.1%payout 9.2%
Net margin8.9%FY2025
Return on equity2.2%TTM
More key figures
Profitability
Return on assets (EBIT)7.1%avg 5y
Operating margin7.2%TTM
Growth
Revenue (TTM)344M CNYTTM
Revenue growth (YoY)−1.4%3y avg +2.3%
Balance sheet & cash flow
Free cash flow72.3M CNYFY2025
Net debt2.4M CNYFY2024 · ≈ 0.0 yrs of FCF
Figures from reported company fundamentals · as of Aug 17, 2026. TTM = trailing twelve months.
Quality Score breakdown
Overall quality65/100
Of which business quality 66
· Market factors (momentum, volatility) 48
Profitability24
Margins and returns on capital today
Quality Growth49
Are margins and returns improving?
Cashflow87
Earnings quality: real cash, not paper profit
Fin. Strength87
Balance sheet, leverage, solvency risk
Investment73
Disciplined investing over empire-building
Low Volatility61
Calm price path (market factor)
Momentum43
Price trend over the last 3–12 months (market factor)
52W Momentum41
Distance to the 52-week high (market factor)
Net Issuance80
Buybacks instead of dilution
Non-valuation factor families (profitability, growth, cashflow, financial strength, momentum …), each academically grounded. Valuation itself sits in the Fair Value and is deliberately excluded here to avoid double-counting.
All values are scores from 0 to 100 (100 = best against fixed, research-based bands), not percentages. The three market factors (momentum, 52-week proximity, low volatility) are displayed but carry zero weight in the headline number: market sentiment is not a business property.
About the company
Shanghai General Healthy Information and Technology Co., Ltd. provides pharmaceutical logistics automation, information technology, and intelligent and mobile medical solutions in China.
Full company description
Shanghai General Healthy Information and Technology Co., Ltd. provides pharmaceutical logistics automation, information technology, and intelligent and mobile medical solutions in China. The company's products include the Smart Pharmacy Project, an intelligent drug management system that combines software and hardware; intelligent static distribution center project, an intelligent intravenous drug configuration and management system; and Intelligent Drug Consumables Management Project, a management system for drug consumables, including poisonous hemp drugs and high-value medical consumables. The company was founded in 2014 and is based in Shanghai, China.
Company description, as reported by the company or data provider.
Revenue & earnings trend
FY2021 – FY2025 · reported fiscal years
Shanghai General Healthy Information and Technology Co. Ltd. reported revenue of 345M CNY in FY2025 versus 490M CNY in FY2021, a compound −8.4%/yr. Reported net income was 30.8M CNY in FY2025, compounding −28.5%/yr from FY2021.
Growth Quality 66/100
Revenue is growing, but margins or cash flow do not fully confirm the trend.
Latest Revenue (FY 2025)
345M CNY
Latest YoY
+8.5%
Avg. revenue growth/yr (3Y) ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump.
+2.3%
Avg. revenue growth/yr (5Y) ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump.
+3.8%
Avg. revenue growth/yr (9Y) ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump.
+6.0%
Value creation/yr (5Y) ⓘEarnings growth per share (CAGR 5 years, EBIT basis) plus dividend yield: value created per share and year.
−18.4%
Earnings growth per share plus dividend yield: the value created per share and year.
Earnings growth per share−18.5%
Dividend yield0.1%
Trend ⓘTwo data points, not a trend model: earnings growth per share over the last 5 fiscal years against the last 10. Labelled "steady" when both rates are within 3 percentage points of each other, otherwise picking up or flattening. Shown only when ten years of history exist.5Y −24.1% vs 10Y −30.1%, picking up
Operating margin (EBIT) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.43.1% (2020) → 16.8% (2025) · falling
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Cite: Fair Value Calculator (2026). "Shanghai General Healthy Information and Technology Co. Ltd. Fair Value". https://www.fairvalue-calculator.com/stock/605186
Peer Group
Medical Devices · 355 stocks
How this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.
Valuation
Quality Score65 · Top 25%
Fair Value upside−81% · Bottom 25%
Profitability
Return on equity (TTM)2% · Above median
Return on assets1% · Below median
Net margin (TTM)9% · Above median
Operating margin (TTM)7% · Above median
Growth and dividend
Revenue growth−1% · Below median
Dividend yield (TTM)0.1% · Bottom 25%
Balance sheet
Debt / equity0.04× · Below median
Valuation Multiples vs Medical Devices median · lower = cheaper
P/E (TTM)107.7× · Priciest 25%
P/B3.28× · Pricier than median
P/S (TTM)10.52× · Priciest 25%
P/FCF7.5× · Pricier than median
EV/EBITDA91.9× · Priciest 25%
What the price implies (reverse DCF)
The inverse question: what free-cash-flow growth must Shanghai General Healthy Information and Technology Co. Ltd. deliver for ten years so that today's price is fair in our DCF model? Same formula, same discount rate as the fair value.
Implied FCF growth, 10 years+21.7 % per year
Achieved revenue growth, 5 years+3.8 % p.a.
Sector median revenue growth+4.4 %
FCF yield on price2.15 %
Discount rate (WACC) in the models10.8 %
The price demands an acceleration versus past growth: a high bar the company still has to clear. Ranking of the largest stocks →
Five quick dimensions, each 0 to 100: VALUE (fair-value potential), FUTURE (revenue growth), PAST (return on equity), HEALTH (low debt), DIVIDEND (yield). Green = this stock, grey = typical sector peer.
This stockSector peers
VALUE0· sector 0
FUTURE0· sector 31
PAST9· sector 5
HEALTH98· sector 97
DIVIDEND2· sector 36
VALUE 0: the price sits above our fair-value range.
Values & ESG
Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.
None of the checked exposures detected
Similar stocks
10 more Medical Devices stocks, each showing price versus our Fair Value estimate (as of Aug 17, 2026).
Is Shanghai General Healthy Information and Technology Co. Ltd. (605186) overvalued or undervalued?
As of Aug 17, 2026, our model estimates a fair value of ¥4.98 versus a price of ¥24.76, about −80% upside (overvalued).
What is the fair value of 605186?
Our model-based fair value for Shanghai General Healthy Information and Technology Co. Ltd. is ¥4.98 (as of Aug 17, 2026), built from audited fundamentals. The current price: ¥24.76.
What is the quality score of 605186?
Shanghai General Healthy Information and Technology Co. Ltd. has a Quality Score of 65/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Shanghai General Healthy Information and Technology Co. Ltd. (605186)?
Our model-based price target is the fair value of ¥4.98 (as of Aug 17, 2026) from 25 valuation models. Cautious scenario ¥3.73, optimistic scenario ¥6.22. It is a calculation from audited fundamentals, not an analyst target.
What is the Shanghai General Healthy Information and Technology Co. Ltd. stock forecast for 2026?
Our models put fair value at ¥4.98, about −80% upside versus a price of ¥24.76 (overvalued). Cautious scenario ¥3.73, optimistic scenario ¥6.22. The calculation is refreshed regularly with new filings.
What is the revenue of Shanghai General Healthy Information and Technology Co. Ltd. (605186)?
Shanghai General Healthy Information and Technology Co. Ltd. reported trailing-twelve-month revenue of about 344M CNY (latest available figure, as of Aug 17, 2026).
What is the net profit margin of 605186?
The net profit margin of Shanghai General Healthy Information and Technology Co. Ltd. is about 8.9%, meaning it keeps roughly 8.9% of revenue as net income. Based on the latest reported figures.
Does Shanghai General Healthy Information and Technology Co. Ltd. pay a dividend?
Shanghai General Healthy Information and Technology Co. Ltd. currently shows a dividend yield of about 0.09% relative to its recent price (as of Aug 17, 2026).
What growth is priced into Shanghai General Healthy Information and Technology Co. Ltd. (605186)?
For today's price to be fair in a discounted-cash-flow model, Shanghai General Healthy Information and Technology Co. Ltd. would have to grow free cash flow by +21.7 % per year for ten years (discount rate 10.8 %, then 2 % perpetual growth). Over the last 5 years revenue grew +3.8 % per year. As of Aug 17, 2026.
What discount rate (WACC) does the fair value of 605186 use?
Our models discount Shanghai General Healthy Information and Technology Co. Ltd. at 10.8 %: a base by market capitalisation (small), damped by beta 0.62, country premium for China. The same rate applies in all 26 models.
What is the intrinsic value of Shanghai General Healthy Information and Technology Co. Ltd. (605186)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Shanghai General Healthy Information and Technology Co. Ltd. it is ¥4.98 per share (as of Aug 17, 2026), against a price of ¥24.76. It is the blended result of 25 valuation models (cash flow, earnings, asset, dividend).
Is Shanghai General Healthy Information and Technology Co. Ltd. stock overvalued or undervalued in 2026?
As of Aug 17, 2026, 605186 trades above its calculated fair value: price ¥24.76, fair value ¥4.98, a gap of about −80% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of 605186?
No. The price is what the market pays today (¥24.76); the fair value is what the company's own numbers justify (¥4.98). For Shanghai General Healthy Information and Technology Co. Ltd. the two are ¥19.78 per share apart. That gap is exactly why we show both numbers side by side.
How much is Shanghai General Healthy Information and Technology Co. Ltd. worth?
The market values Shanghai General Healthy Information and Technology Co. Ltd. at about 3.4B CNY (market capitalisation, as of Aug 17, 2026). Per share that is ¥24.76; our models calculate a fair value of ¥4.98 per share.
What do the bullish and bearish scenarios say about 605186?
Our models span a range for Shanghai General Healthy Information and Technology Co. Ltd.: cautious scenario ¥3.73, base ¥4.98, optimistic ¥6.22 per share (as of Aug 17, 2026, price ¥24.76). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the P/E ratio of 605186?
Shanghai General Healthy Information and Technology Co. Ltd. trades at a price-to-earnings ratio of 107.7 (as of Aug 17, 2026). A P/E on its own says little: it compares the price with ONE year of profit, while our fair value of ¥4.98 is built from several models across several years. Other multiples: P/B 3.3, P/S 10.5, EV/EBITDA 91.9.
How solid is the balance sheet of Shanghai General Healthy Information and Technology Co. Ltd. (605186)?
Balance-sheet figures for Shanghai General Healthy Information and Technology Co. Ltd. (as of Aug 17, 2026): return on equity 2.2%, debt of 0.04 per unit of equity. They feed the Quality Score of 65/100, which measures business quality independently of the share price.
How far is 605186 from its 52-week high?
Shanghai General Healthy Information and Technology Co. Ltd. trades at ¥24.76, about 32% below its 52-week high of ¥36.50 and 36% above the low of ¥18.15 (as of Aug 17, 2026). Distance from the high says nothing about value: that is what the fair value of ¥4.98 is for.
Which stocks are comparable to Shanghai General Healthy Information and Technology Co. Ltd.?
From the same area (Healthcare) we also value Abbott Laboratories,, Stryker Corporation, Medtronic plc, Boston Scientific Corporation, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Shanghai General Healthy Information and Technology Co. Ltd. stock attractive at the current price?
The data as of Aug 17, 2026: price ¥24.76, calculated fair value ¥4.98 (−80%), Quality Score 65/100, from 25 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of 605186 calculated?
We run Shanghai General Healthy Information and Technology Co. Ltd. through 25 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of ¥4.98, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 32.6 % above its aggregate fair value. Shanghai General Healthy Information and Technology Co. Ltd. itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on <a href="/is-it-worth-investing-now/">is it worth investing now</a>.
Free · no account needed
Watch Shanghai General Healthy Information and Technology Co. Ltd. in the live analysis
One click puts Shanghai General Healthy Information and Technology Co. Ltd. on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.
